Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Eisai claims novel cytidine deaminase inhibitors

Nov. 15, 2010

Wyeth discovers new inhibitors of PI3K-alpha and mTOR

Nov. 15, 2010

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Nov. 12, 2010

CytRx begins pharmacokinetic bafetinib trial in patients with brain cancer

Nov. 12, 2010

Canadian scientists identify new antimitotic agents

Nov. 12, 2010

Novel mTOR inhibitors presented by Merck & Co.

Nov. 12, 2010

Choongwae Pharma claims new reverse-turn mimetics for treatment of AML

Nov. 12, 2010

Clavis Pharma and Clovis Oncology sign additional agreement for CP-4126

Nov. 12, 2010

Novartis discontinues clinical program for anticancer candidate ASA-404

Nov. 12, 2010

Astex's AT-9283 enters phase II trial in multiple myeloma

Nov. 12, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...